<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025181</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068934 (10M-00-4)</org_study_id>
    <secondary_id>LAC-USC-10M004</secondary_id>
    <secondary_id>MDX-MDXCTLA4-03</secondary_id>
    <secondary_id>NCI-4210</secondary_id>
    <nct_id>NCT00025181</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery</brief_title>
  <official_title>An Open-label Study Of MDX-CTLA4 In Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Resected Stage III Or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells. Vaccines made from a person's&#xD;
      cancer cells may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining monoclonal antibody therapy&#xD;
      and vaccine therapy in treating patients who have stage III or stage IV melanoma that has&#xD;
      been removed during surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and adverse event profile of anti-cytotoxic T-lymphocyte-associated&#xD;
           antigen-4 monoclonal antibody combined with tyrosinase:368-376, gp100:209-217, and&#xD;
           MART-1:26-35 peptides emulsified in Montanide ISA-51 in patients with resected stage III&#xD;
           or IV melanoma.&#xD;
&#xD;
        -  Determine if this regimen causes antigen-specific T-cell activation in these patients.&#xD;
&#xD;
        -  Determine the clearance profile of this regimen in these patients.&#xD;
&#xD;
        -  Assess the development of host immune response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of anti-cytotoxic T-lymphocyte-associated antigen-4&#xD;
      monoclonal antibody (MDX-CTLA4).&#xD;
&#xD;
      Patients receive tyrosinase:368-376, gp100:209-217, and MART-1:26-35 peptides emulsified in&#xD;
      Montanide ISA-51 subcutaneously followed by MDX-CTLA4 IV over 90 minutes at 0, 1, 2, 3, 4, 5,&#xD;
      8, and 11 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of at least 6 patients receive escalating doses of MDX-CTLA4 until the maximum&#xD;
      tolerated dose is determined.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">19</enrollment>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed completely resected stage III or IV melanoma&#xD;
&#xD;
               -  Mucosal or ocular subtypes allowed&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
          -  Positive staining of tumor tissue with antibody HMB-45 for gp100, tyrosinase, and/or&#xD;
             MART-1&#xD;
&#xD;
          -  Failed (or ineligible for or refusal of) interferon alfa&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Hematocrit at least 30%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 1.25 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody nonreactive&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.25 times ULN&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  Antinuclear antibody (ANA) negative OR&#xD;
&#xD;
          -  If ANA positive, must be:&#xD;
&#xD;
               -  Antithyroglobulin antibody negative&#xD;
&#xD;
               -  Rheumatoid factor negative&#xD;
&#xD;
               -  Anti-LKM antibody negative&#xD;
&#xD;
               -  Anti-phospholipid antibody negative&#xD;
&#xD;
               -  Anti-islet cell antibody negative&#xD;
&#xD;
               -  Anti-neutrophil cytoplasmic antibody negative&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No autoimmune disease (e.g., uveitis or autoimmune inflammatory eye disease)&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No hypersensitivity to tyrosinase:368-376, gp100:209-217, MART-1:26-35, or Montanide&#xD;
             ISA-51&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No underlying medical condition that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody&#xD;
&#xD;
          -  No prior tyrosinase, gp100, or MART-1 peptide&#xD;
&#xD;
          -  No prior antitumor vaccination&#xD;
&#xD;
          -  No prior interleukin-2&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy for melanoma&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy for melanoma&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy for melanoma&#xD;
&#xD;
          -  At least 4 weeks since prior corticosteroids&#xD;
&#xD;
          -  No concurrent systemic or topical corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy for melanoma&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior cytotoxic therapy&#xD;
&#xD;
          -  At least 4 weeks since any other prior therapy for melanoma&#xD;
&#xD;
          -  Concurrent analgesics allowed if on stable dose for at least 2 weeks before study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey S. Weber, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, small size</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

